Drugs / MabCampath
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | MabCampath | — | 2012-08-08 | europa.eu ↗ |
| Approved | EU (EMA) | MabCampath | — | 2001-07-06 | europa.eu ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT02711202 Comparator | Jan 2007 → Mar 2009 | — | Institute for Clinical and Experimental Medicine | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MabCampath | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02711202 ↗ |
| Modality | Monoclonal antibody | “anti-CD52 MabCampath (Alemtuzumab) a single dose of anti-TNF-α Remicade (infliximab) monoclonal antibodies” NCT02711202 ↗ |